The Randomized EtaNErcept Worldwide evALuation (RENEWAL) trial evaluated the TNF-α antagonist etanercept in patients with HF and New York Heart Association (NYHA) class II-IV with a LVEF ≤ 30%. Here, TNF is linked to hydrops fetalis.